

March 15, 2011

## Oh That? Seroquel Marketing Undeterred by This Week's Deceptive Marketing Settlement By Martha Rosenberg


Google the word "depression" and the first search result you'll get is for the antipsychotic Seroquel XR.

Visit WebMD and the home page hosts similar ads for Seroquel XR, above and adjacent to the lead news story.

Who would know AstraZeneca inked the largest multi-state consumer protection settlement on record relating to deceptive Seroquel marketing just this week? For \$68.5 million? Only a year after inking a similar settlement related to burying side effect and safety information for \$520 million with the government?

Who would know AstraZeneca has already settled nearly 25,000 personal injury lawsuits pertaining to Seroquel with more to come says ABC news?

First approved in 1997,
Seroquel has enjoyed the
camel-nose-under-thetent phenomenon known
as indications creep. First
approved for
schizophrenia, it was later
approved for bipolar
disorder and psychiatric
conditions in children. But
it was Seroquel's 2009



approval as an add-drug for depression that helped it reach its spectacular sales of \$5.3 billion in 2010 thanks to the US' walloping depression "market" of 20 million.

Seroquel's blood sugar, weight gain and heart side effects are well known. That's why FDA regulators opposed its use as a first choice, stand-alone treatment for the 10 percent of the US population with depression when safer drugs exist. "I saw no clear advantage demonstrated in efficacy," said Dr. Wayne Goodman who chaired the FDA panel considering the depression indication. "There were side effects, and I would expect unintended consequences associated with wide-scale use of the drug."

The drug also can cause increased mortality in elderly patients with dementia-related psychosis, suicidality, neuroleptic malignant syndrome, cataracts, seizures, increases in blood pressure and movement disorders in neonates when their mothers take it. Seroquel's fraud trail is also well known with more than six conflict of interest scandals swirling around Seroquel researchers and promoters. Psychiatrist Richard Borison was sentenced to a 15-year prison sentence in 1998 for a pay-to-play Seroquel research scheme which helped establish Seroquel's original perception as safe.

But how many realize Seroquel's cost to the individual taxpayer and health insurance consumers at a Red Book price of almost \$500 per month per person?

Auditors with the Michigan Corrections Department say the state could save \$350,000 a month by switching just half of its Seroquel prescriptions to another pill. (Anyone know a school that could use \$350,000 a month?) And North Carolina spends \$29.4 million per year on Seroquel prescriptions. Who knows how much else states and taxpayers are paying to control the metabolic side effects that emerge with Seroquel? Reports are also starting to surface about the effect \$6,000-a-year Seroquel prescriptions, many unnecessary and inappropriate, are having on rising insurance premiums themselves for private insurance holders.

In fact, the public is really paying twice for the irrepressible Seroquel marketing. First for drug purchases in state and private plans (and the advertising) and second in side effects from a drug whose safety continues to be in doubt.



Chicagoan Martha Rosenberg frequently writes about the impact of the pharmaceutical, food and gun industries on public health. Her work has appeared in the Boston Globe, San Francisco Chronicle, Chicago Tribune and other outlets.

She is a feature writer for the <u>Consumers Digest.</u>

Martha is a gifted writer, a talented editorial cartoonist, and a friend.